

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Benjamin Oshlack et al.
Serial No.: 10/562,494
Art Unit: 1617
Filed: September 9, 2004
For: **PHARMACEUTICAL COMBINATIONS OF
HYDROCODONE AND NALTREXONE**
Examiner: Deirdre Renee CLAYTOR
Confirmation No.: 8290
Docket No.: 200.1163US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA, 22313-1450

February 25, 2010

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (1 sheet) for consideration by the Examiner in connection with the examination of the above-identified patent application.


Applicants respectfully note that documents A04 to A06 were cited in the Office Action issued on November 10, 2009, in connection with corresponding Japanese Patent Application No. 2006-528039.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of the documents are enclosed.

It is respectfully requested that the documents listed on the accompanying Form PTO-1449 (1 sheet) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), “[b]efore the mailing of a first Office action after the filing of a request for continued examination under § 1.114.” See 37 C.F.R. §1.97(b). Accordingly, it is believed that no fee is due. If it is determined that any fees are due in connection with the filing of this Information Disclosure Statement, the Commissioner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Oleg Igselevich
Reg. No. 56,963

DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940